Unintended consequences: Renaming botulinum neurotoxin-producing species of clostridium and related species.

Botulinum neurotoxin Botulinum neurotoxin-producing clostridia Clostridium botulinum Taxonomy

Journal

Toxicon : official journal of the International Society on Toxinology
ISSN: 1879-3150
Titre abrégé: Toxicon
Pays: England
ID NLM: 1307333

Informations de publication

Date de publication:
01 Mar 2023
Historique:
received: 28 11 2022
revised: 05 01 2023
accepted: 20 01 2023
pubmed: 25 1 2023
medline: 3 3 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

Botulinum neurotoxin-producing species of Clostridium are highly diverse. Clostridium botulinum could represent at least four different species of Clostridium. In addition, strains that do not produce botulinum neurotoxin are closely related to toxigenic strains, probably representing the same species. Although reclassification of these organisms has been proposed in the past, their species names have remained unchanged, mainly because of the premise that changing names of medically relevant organisms might cause confusion in the healthcare and scientific community. In this review, we discuss the possible unintended consequences of reclassifying botulinum neurotoxin-producing species of Clostridium, which are of public health, medical, and biodefense interest.

Identifiants

pubmed: 36693544
pii: S0041-0101(23)00022-3
doi: 10.1016/j.toxicon.2023.107036
pii:
doi:

Substances chimiques

Botulinum Toxins EC 3.4.24.69

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107036

Informations de copyright

Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Carolina Lúquez (C)

Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: CLuquez@cdc.gov.

Jessica L Halpin (JL)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Janet Dykes (J)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

Humans Hemifacial Spasm Neuromuscular Agents Treatment Outcome Botulinum Toxins, Type A

Botulinum Toxin Treatment of Psoriasis-A Comprehensive Review.

Ali Ghaseminejad-Bandpey, Shahroo Etemadmoghadam, Bahman Jabbari
1.00
Psoriasis Humans Animals Botulinum Toxins

Influence of vitamin D on muscle strength and botulinum toxin dosage through surface electromyography.

Marcelle Simões Coelho, Gabriel Cirone Lopes, Luigi Giovanni Bernardo Sichi et al.
1.00
Humans Electromyography Muscle Strength Vitamin D Male
Humans Male Aged Bacteremia Clostridium Infections

Classifications MeSH